GlassScriptPhysician profile
Alisha K Johnson
NPI 1558771006
$689.42
in general payments reported to CMS, 2019-2025
22 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $355 · 2024: $199 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $689.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $67.59 | 2023-2024 | |
| Novo Nordisk INC | $66.82 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $64.20 | 2023-2025 | |
| Astellas Pharma US INC | $57.32 | 2023-2024 | Veozah, Myrbetriq |
| Amgen INC. | $51.13 | 2023-2024 | Prolia, Evenity |
| Ani Pharmaceuticals, INC. | $38.17 | 2025 | Purified Cortrophin Gel |
| Abbott Laboratories | $33.79 | 2024-2025 | Freestyle Libre 3 |
| Insulet Corporation | $29.91 | 2025 | Omnipod |
| Lilly USA, LLC | $26.72 | 2023-2024 | Mounjaro |
| Axsome Therapeutics, INC. | $24.10 | 2023 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.09 | 2024 | Trulance, Xifaxan |
| Hologic Sales and Service, LLC | $21.90 | 2025 | Aptima, Thinprep 2000 Processor |
| Sumitomo Pharma America, INC. | $21.36 | 2023 | Gemtesa |
| Indivior INC. | $21.05 | 2024 | Sublocade |
| Paratek Pharmaceuticals, INC. | $20.91 | 2023 | Nuzyra |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $20.19 | 2023 | Trelegy Ellipta |
| Halozyme INC | $18.60 | 2023 | |
| Lundbeck LLC | $17.77 | 2023 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $17.71 | 2023 | Breztri |
| Shield Therapeutics INC | $17.49 | 2023 | Accrufer |
| Idorsia Pharmaceuticals US INC | $15.64 | 2023 | Quviviq |
| Radius Health, INC. | $14.96 | 2023 | Tymlos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alisha Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.